



ANNOUNCEMENT

ADHERIUM'S SMARTINHALER™ PLATFORM TO BE USED BY ASTRAZENECA FOR US COPD STUDY

13 June 2016: Adherium Limited (ASX: ADR), a global leader in digital health technologies that address sub-optimal medication use in chronic disease, today announced that AstraZeneca will use Adherium's Smartinhaler™ platform in an important new US clinical study that aims to improve medication adherence in patients with Chronic Obstructive Pulmonary Disease (COPD).

The study will be conducted at seven US healthcare centres, and enroll nearly 400 COPD patients, starting in August. The study will end after 12 months.

"This study is important research because adherence rates in COPD patients are low, and Adherium's Smartinhaler™ is the gold standard in recording and improving medication adherence in chronic lung disease. Adherium is supplying the technology platform for this study under the long term Master Supply and Development Agreement already entered into with AstraZeneca," said Adherium's Group CEO Garth Sutherland.

The SmartTouch™ Symbicort® device that will be used in this study features a modernized industrial design, miniaturization of electronic sensors, and improved usability, each showcasing the investment Adherium has made in its technology since listing on the Australian Securities Exchange in August 2015.

****ENDS****

For personal use only

ABOUT ADHERIUM

Adherium (ASX:ADR) is an Australian Securities Exchange listed company which develops, manufactures and supplies digital health technologies which address sub-optimal medication use and improve health outcomes in chronic disease.

Adherium is a provider of digital health solutions to pharmaceutical, remote patient monitoring and clinical trials companies and organizations. The Company's proprietary Smartinhaler™ platform has been independently proven to improve medication adherence and health outcomes for patients with chronic respiratory disease. Adherium has the broadest range of "smart" medication sensors for respiratory medications globally.

Clinical outcomes data has proven that the Smartinhaler™ platform can improve adherence by up to 59% in adults and 180% in children and reduce severe episodes by 60% in adults. In addition, interim data from a study at the University of Sheffield demonstrated a 144% increase in adherence, a restoration of lung function to 100% and a 37% reduction in oral steroids indicating reduced severe exacerbations in children. Both children and adults benefit from improved quality-of-life as a result of their improved adherence, demonstrating a substantial gain over current best practice treatment.

The Smartinhaler™ platform has so far been used in 63 projects (clinical, device validation or other) and has been referenced in 33 peer reviewed journal articles. The Company has received FDA 510(k) notifications for clearance to market and CE Marks for its devices and software, which allows it to sell these devices into international markets.

www.adherium.com
www.smartinhaler.com

Enquiries:

At the Company	Media enquiries
North America James Hattersley Senior Vice President, Business Development M: +1 (610) 955 5886 E: jamesh@adherium.com	AU/NZ/ Media Rudi Michelson Monsoon Communications D: +61 (0)3 9620 3333 E: rudim@monsoon.com.au
Europe John Tarplee Senior Vice President, Business Development M: +44 (0)7917 701846 E: johnt@adherium.com	Rob Turnbull CFO & Joint Company Secretary M: +64 21 887 628 E: robt@adherium.com